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systems geneticsThe ATP-binding cassette, sub-family B member 4 knock-out mouse (Abcb4−/−) is a relevant model for
chronic cholangiopathy in man. Due to the lack of this P-glycoprotein in the canalicular membrane of hepa-
tocytes, the secretion of phospholipids into bile is absent, resulting in increased bile toxicity. Expression of
insulin like growth factor binding protein 5 (Igfbp5) increases in time in the livers of these mice. It is unclear
whether this induction is a consequence of or plays a role in the progression of liver pathology. The aim of
this study was therefore to investigate the effect of IGFBP5 induction on the progression of liver ﬁbrosis
caused by chronic cholangiopathy. IGFBP5 and, as a control, green ﬂuorescent protein were overexpressed
in the hepatocytes of Abcb4−/−mice, using an adeno-associated viral vector (AAV). Progression of liver ﬁbro-
sis was studied 3, 6, and 12 weeks after vector injection by analyzing serum parameters, collagen deposition,
expression of pro-ﬁbrotic genes, inﬂammation and oxidative stress. A single administration of the AAV vec-
tors provided prolonged expression of IGFBP5 and GFP in the livers of Abcb4−/−mice. Compared to GFP con-
trol, fractional liver weight, extracellular matrix deposition and amount of activated hepatic stellate cells
signiﬁcantly decreased in IGFBP5 overexpressing mice even 12 weeks after treatment. This effect was not
due to a change in bile composition, but driven by reduced inﬂammation, oxidative stress, and proliferation.
Overexpression of IGFBP5 seems to have a protective effect on liver pathology in this model for chronic
cholangiopathy.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Abcb4−/− (ATP-binding cassette, subfamily b, member 4) mice
are the model for progressive familial intrahepatic cholestasis type
3. In humans, ABCB4 deﬁciency results in spontaneous development
of biliary ﬁbrosis shortly after birth, due to the lack of biliary phos-
pholipids essential for neutralizing the toxic effects of the high con-
centrations of bile acids [1]. Since murine bile acids are less toxic,/−, ATP-binding cassette, sub-
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l rights reserved.the phenotype is milder in mice than in humans, which also qualiﬁes
Abcb4−/− mice as a model for other forms of progressive cholangio-
pathies, such as progressive sclerosing cholangitis [2,3]. Recurrent
chronic injury in this mouse model, caused by leakage of toxic bile
into the portal area leads to progressive accumulation of extracellular
matrix (ECM) components, mainly produced by activated hepatic
stellate cells (HSC) in an attempt to counter hepatic damage [4–6].
This results in an imbalance between ﬁbrogenesis and ﬁbrolysis, lead-
ing to liver ﬁbrosis, architectural distortion, cirrhosis and ultimately
liver failure [7,8].
Insulin like growth factor binding protein 5 (Igfbp5) is strongly in-
duced in the livers of Abcb4−/− mice suggesting a potential role in
the pathogenesis of chronic cholangiopathy [9]. This seems to be sup-
ported by its high expression in patients with cholangiocarcinoma
[10]. We have shown previously that overexpression of IGFBP5 in-
creases the survival of partially activated HSC and myoﬁbroblasts
(MF) [11]. This pointed to its proﬁbrotic role in liver, as also reported
for skin and lung where IGFBP5 overexpression stimulates the pro-
gression of ﬁbrosis [12,13].
To clarify the role of IGFBP5 in the pathogenesis of chronic cholan-
giopathies, we overexpressed it in the Abcb4−/− mice, using an
adeno-associated viral (AAV) vector. This in vivo AAV delivery that
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supply of large amounts of this secretory protein to the intracellular
space and to the HSC [14]. To substantiate the experimental ﬁndings
in this model, and to relate them to the physiological role of hepatic
IGFBP5 expression, a systems genetics approach was applied to a
mouse genetic reference population, using the open source GeneNet-
work database. The results have pointed to a beneﬁcial role of IGFBP5
in liver ﬁbrosis caused by chronic cholangiopathy in Abcb4−/−mouse
model.
2. Materials and methods
2.1. scAAV vectors
scAAV8-LP1-Igfbp5 and scAAV8-LP1-eGFP were generated by
replacing the factor IX cDNA from scAAV-LP1-IX by the cDNA of
mouse Igfbp5 or eGFP, using the EcoR1 and Bspm1 sites (Fig. 1A)
[15]. Correctness of constructs was checked by sequencing. scAAV8
pseudotyped vector was produced and titrated as described [16].
2.2. Animals
The animal studies were reviewed and approved by the AMC com-
mittee for animal care and use. Three months after birth, a single dose
of 5×1012 genomic copies (gc)/kg body weight of scAAV8-LP1-Igfbp5
or scAAV8-LP1-eGFP was injected in the tail vein of male FVB and
Abcb4−/− mice (FVB background). Animals were sacriﬁced 3
(n=5), 6 (n=7) and 12 (n=7) weeks thereafter. In FVB controls
(n=5) the effect was studied only after 3 weeks. Five animals per
treatment group were used at 3 weeks, and 7 animals per group at
weeks 6 and 12.
2.3. Tissue collection and biochemical analyses
Upon sacriﬁcing, blood was collected, livers were snap-frozen in
liquid nitrogen and stored at −80 °C, or ﬁxed in 4% formaldehyde
in PBS. Total liver collagen was determined by measuring hydroxy-
proline content as described [17]. GSH/GSSG ratio in liver and bileFig. 1. Overexpression of IGFBP5 in liver using AAV. (A) Time course and genome structure o
(30kD; right panel) present in liver homogenates obtained 3, 6 and 12 weeks after injec
overexpressing animals are on the left (“g”) and IGFBP5-overexpressing mice (“i”) on the r
GFP, while those in the right panel were incubated with an anti-IGFBP5 antibody. Every
were analyzed. (C–D) Relative gene expression of Igfbp5 in Abcb4−/−mice 3, 6 and 12 week
(left panel) (n=5-7). Asterisks denote signiﬁcance (pb0.05) in comparison with control trwas determined [18]. ASAT, ALAT and alkaline phosphatase (ALP)
concentrations in blood were determined using standard clinical
chemistry methods.2.4. RNA isolation, reverse transcription and quantitative PCR
These analyses were performed and analyzed as previously de-
scribed [11]. We used 5–7 animals for qRT-PCR, depending on the
time point—5 animals per group at 3 weeks, and 7 animals per
group at 6 and 12 weeks.2.5. Western blot analysis
Western blot analysis was performed as described [11], using the
following antibodies: IGFBP5 (Abcam, Cambridge, UK), GFP, PCNA
and p21 (Santa Cruz Biotechnology, CA, USA). Goat anti-mouse
(Bio-Rad Laboratories, Veenendaal, The Netherlands) and goat anti-
rabbit IgG horseradish peroxidase conjugated (Santa Cruz Biotechnol-
ogy, CA, USA) were used as secondary antibodies. Chemilumines-
cence was quantiﬁed by Lumi-Imager F1, using CDP-Star (Roche,
Mannheim, Germany) and β-actin as a reference. For detection of
IGFBP5 in serum, the same amount of (10x diluted) serumwas loaded
for each sample.2.6. Histology and immunohistochemistry
Formaldehyde-ﬁxed liver sections were stained with Sirius red
(morphometrical connective tissue assessment), or immunohisto-
chemically, as described [19]. Antibodies directed against PCNA
(Santa Cruz biotechnology, CA, USA) andα-SMA (Sigma, Zwijndrecht,
The Netherlands) were visualized with goat anti-mouse or goat anti-
rabbit IgG coupled to horse-radish peroxidase (Sigma, Zwijndrecht,
The Netherlands), or alkaline phosphatase, respectively. Anti-α-F4/
80 (AbDSerotec, Dusseldorf, Germany) and anti-MAC-1 (R&D systems,
Abingdon UK) were both visualized using rabbit-anti-rat-biotin as
secondary antibody (DAKO, Glostrup, Denmark).f scAAV-LP1-Igfbp5 and scAAV-LP1-GFP. (B) Western blot of GFP (left panel) and IGFBP5
tion, and of IGFBP5 in plasma after 3 weeks (right panel). In both panels, the GFP-
ight side. For detection, the Western blots in the left panel were incubated with anti-
lane represents an individual animal. In total, 4–6 animals of each treatment group
s after administration of scAAV-LP1-Igfbp5 (right panel) or scAAV-LP1-GFP as a control
eatment.
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These analyses were performed as described [20] and detailed in
Supplementary ﬁle 1.
2.8. Statistical analysis
ANOVA and Student's t-test were used. The error bars represent
the standard deviation, and signiﬁcance threshold was set to pb0.05.
3. Results
3.1. IGFBP5 overexpression reduces hepatocyte damage and proliferation
in Abcb4−/− mice
To investigate the effect of IGFBP5 on the liver pathogenesis in
Abcb4−/− mice, its expression was increased in hepatocytes using
the liver speciﬁc scAAV8-LP1-IGFBP5 vector and scAAV8-LP1-GFP as
a control (Fig. 1A). qPCR and Western blot conﬁrmed the hepatic
overexpression of both transgenes 3, 6 and 12 weeks after
injection(Fig. 1B). During this period, the expression declined, but
was still signiﬁcantly increased for Igfbp5 at 12 weeks (~15-fold)
compared to mock transduction (Fig. 1C). Because of the ongoing he-
patocyte proliferation in the Abcb4−/−mice this loss of episomal AAV
vectors was expected [21,22]. The lower expression of GFP seen at
3 weeks after injection while the vector dose was equal, suggested a
more rapid decline of GFP expression during this period, which
could be due to a higher hepatocyte proliferation rate in these control
mice (Fig. 1D). Therefore, the expression of proliferation markers
PCNA and Ki67 was determined (Fig. 2A–C). The 2–3 fold lower
PCNA expression level after three weeks, and the lower expression
level of Ki67 at both later time points, conﬁrmed that proliferation
was reduced in mice overexpressing IGFBP5. This may be due to en-
hanced expression of p21, involved in repair of DNA damage by ar-
resting cell cycle and proliferation. Both p21 mRNA and protein
expression level were signiﬁcantly upregulated in Igfbp5 injected an-
imals (Fig. 3A–B). This was accompanied by an increased presence ofFig. 2. IGFBP5 overexpression decreases liver cell proliferation in Abcb4−/−mice. (A) Repr
(control) or scAAV-LP1-Igfbp5 (IGFBP5). (B) Quantiﬁcation of PCNA expressing nuclei in
(C) mRNA level of Ki67 in liver after 3, 6 and 12 weeks determined by qPCR expressed as psenescence-associated β-galactosidase (a widely used biomarker for
senescent and aging cells), especially in ﬁbrotic regions (Fig. 3C).
Lower ALP (alkaline phosphatase) and ASAT (aspartate transami-
nase) levels in these mice 6, 9 and 12 weeks after injection, suggested
that IGFBP5 alleviates hepatocyte damage (Fig. 3D–E).
3.2. Overexpression of IGFBP5 reduces liver ﬁbrosis in Abcb4−/− mice
A protective role of IGFBP5, as suggested by decreased hepatocyte
proliferation and lowered liver enzymes in serum, may also slow
down the progression of ﬁbrosis. The 20% lowered fractional liver
weight, the reduced presence of ECM shown by hydroxyproline con-
tent (Fig. 4A–B) and Sirius red staining (Fig. 4C and Supplementary
Fig. 1A) all conﬁrmed that IGFBP5 overexpression impairs the pro-
gression of liver ﬁbrosis in this model. This was supported by 70% re-
duction of α-SMA (marker for activated HSC/MFs) expressing HSC/
MFs 12 weeks after vector administration (Fig. 5A–B), and, as a conse-
quence, reduced expression of procollagen, collagens 1, 3, 4 and
Timp1 (Fig. 5C–G).
Since the pathogenesis in the Abcb4−/− mouse results from toxic
bile, an effect of IGFBP5 on bile composition could provide an alterna-
tive explanation of its protective role in this model. The absence of
signiﬁcant differences in bile composition 12 weeks after vector ad-
ministration however renders this explanation highly unlikely
(Table 1).
3.3. IGFBP5 overexpression reduces inﬂammation and oxidative stress in
the liver of Abcb4−/− mice
IGFBP5 has been reported to impair the inﬂux of proinﬂamma-
tory cells [23]. Inﬂux of these cells into the liver will result in the
release of inﬂammatory mediators that enhance ﬁbrosis and cause
oxidative stress [24]. Inhibition of this inﬂux by IGFBP5 may there-
fore explain the protective effect observed in this model. To inves-
tigate this, markers for inﬂammatory cells were studied. Presence
of F4/80, a marker for inﬁltrating macrophages and liver-residentesentative PCNA immunostaining in liver at 3 weeks after injection of scAAV-LP1-GFP
control (GFP) or IGFBP5 overexpressing mice per mm2 at 3 weeks after treatment.
ercentage of the control. Asterisks denote signiﬁcance (pb0.05).
Fig. 3. IGFBP5 overexpression reduces hepatocyte damage in Abcb4−/− mice. (A) Gene expression of p21 in liver after 3, 6 and 12 weeks after vector administration. (B) p21 level
12 weeks after vector administration as detected by Western blot, and quantiﬁed as percentage of the control (GFP). Asterisks denote signiﬁcance (pb0.05). (C) Representative
SA-β-gal staining of control (GFP) and IGFBP5-treated animals 12 weeks after vector injection. (D–E) Plasma concentrations of ALP and ASAT in GFP- and IGFBP5-treated
Abcb4−/−mice 1, 3, 6, 9, and 12 weeks upon vector administration.
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12 weeks (protein) after vector administration (Fig. 6A–C). Expres-
sion of Mpo, a marker for inﬁltrating neutrophils, was reduced at
all three time points (Fig. 6B). Furthermore, the presence of
MAC1-expressing activated macrophages was clearly reduced in
IGFBP5 overexpressing animals (Fig. 6D). In addition, the expres-
sion of Mcp1, which plays a role in the recruitment of monocytes
to sites of injury and infection, was reduced 3 and 6 weeks upon
IGFBP5 administration (Fig. 6E). Finally, Tgfβ1 mRNA level was
also reduced in Abcb4−/− mice overexpressing IGFBP5 (Fig. 6F).Fig. 4. IGFBP5 overexpression reduces liver ﬁbrosis in Abcb4−/−mice. (A) Average fractiona
administration. (B) Hydroxyproline amount in liver 6 and 12 weeks after viral treatment. A
(GFP) and IGFBP5 overexpressing livers 12 weeks after experiment started.The reduced inﬂux caused by IGFBP5 overexpression will also
lower the release of proinﬂammatory cytokines in liver and as
such may explain the lower the oxidative stress in these livers as
indicated by the signiﬁcant increased ratio of glutathione (GSH)
and its oxidized form glutathione-disulﬁde (GSSG; Supplementary
Fig. 1C). In support, mRNA expression level of heme oxygenase 1
was signiﬁcantly upregulated upon injection of IGFBP5 (Supple-
mentary Fig. 1D).
Speciﬁc expression of GFP in hepatocytes did not induce an im-
mune response, as shown by the lack of anti-GFP antibodies inl liver weight of control and IGFBP5 overexpressing mice 6 and 12 weeks after vector
sterisks denote signiﬁcance (pb0.05). (C) Representative Sirius red staining in control
Fig. 5. IGFBP5 overexpression decreases expression of ﬁbrotic markers in Abcb4−/−mice. (A) Representative α-SMA staining in control (GFP; left panel) and IGFBP5 overexpressing
livers (right panel) 12 weeks after vector administration. (B) Number of α-SMA expressing cells per mm2 in liver 12 weeks after vector administration as determined by a custom
written counting macro in Scion Image (Scion Corp, Frederick, MD). (C–F) Relative mRNA level for procollagen, collagens 1, 3, 4 and Timp1, after 3, 6 and 12 weeks. All results are
given as a percentage of the control. Asterisks denote signiﬁcance (pb0.05).
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non-treated and GFP-treated Abcb4−/− mice (Supplementary Fig.
2F). This conﬁrms previous ﬁndings of our group and others thatTable 1
Bile salt composition of GFP control and IGFBP5-treated Abcb4−/− mice and FVB.
FVB Abcb4−/− ctrl Abcb4−/− BP5
tauro β-muricholate 223.52±67.90 277.96±142.05 253.98±172.18
taurocholate 94.97±22.84 145.85±68.17 180.53±162.50
tauro α-muricholate 1.92±0.84 6.73±4.86 9.33±7.36
tauroursodeoxycholate 0.35±0.14 0.74±0.36 1.18±0.89
taurochenodeoxycholate 1.56±0.59 4.36±1.66 5.55±3.14
∑ (bile salts) 322.32±85.73 435.65±209.62 450.58±334.74hepatocyte speciﬁc expression provided by an AAV vector does
not result in an immune response towards the transgene [16].
Altogether these data support an anti-inﬂammatory effect of
IGFBP5 in the liver of Abcb4−/− mice.
3.4. Co-variation of Igfbp5 expression with phenotypic traits in a mouse
genetic reference population supports its anti-inﬂammatory role
To gain insight into the physiological role of Igfbp5 expression in
adult liver, its co-variation with published phenotypic traits in the
BXD genetic reference population (GRP) was analyzed. This experi-
mental model that incorporates the natural range of genetic variation
is obtained by 20 generation inbreeding in the F2 mice from an inter-
cross between C57BL/6J and DBA/2J strains (www.genenetwork.org)
Fig. 6. IGFBP5 reduces expression of inﬂammatory markers and oxidative stress. (A, B, E and F) Relative mRNA levels of F4/80, Mpo, Mcp1 and Tgfβ1, respectively, in livers of control
(GFP) and IGFBP5 overexpressing mice, 3, 6 and 12 weeks upon vector administration. All results are given as a percentage of the control (GFP). Asterisks denote signiﬁcance
(Pb0.05). (C and D) Representative pictures of immunostainings for F4/80 and MAC1, respectively, 12 weeks after vector administration.
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tween liver Igfbp5 expression and plasma concentrations of ALAT
and ASAT (Supplementary Fig. 2A and B) [27]. These relationships un-
derline a hepato-protective role of IGFBP5. The negative correlation
between Timp1 and Igfbp5 expression in the BXD GRP livers [5] pro-
vides further support for a possible physiological role of IGFBP5 in
ECM remodeling (Supplementary Fig. 2C). In the reference popula-
tion, the expression of pro-ﬁbrotic cytokine Tgfβ1 positively correlat-
ed with that of F4/80 (Supplementary Fig. 2D), which corroborated
the reduction of inﬂammatory response by IGFBP5.
Furthermore, the correlation of IGFBP5 expression in liver of BXD
GRP with clinical phenotypes was calculated. A number of pheno-
types was related to immune function (Supplementary ﬁle 2),
which was consistent with the anti-inﬂammatory effect of IGFBP5 inthe liver of Abcb4−/− mice. Igfbp5 expression in the livers of BXD
mice negatively correlated with inﬂammation in spleen, bone mar-
row and with a general inﬂammatory response, the exception being
a positive correlation with TBC infection in the lung (Supplementary
Fig. 2E).
3.5. Tissue speciﬁc regulation of Igfbp5 expression
Given the unanticipated effect of IGFBP5 on liver ﬁbrosis, we
addressed the tissue-speciﬁcity of its expression. Notably, a direct
analysis of variation in Igfbp5 mRNA levels in different organs—liver,
kidney, (whole) brain, hippocampus and cartilage—did not reveal
any correlation (not shown), underscoring organ speciﬁc regulation
of Igfbp5 expression. The correlations between Igfbp5 expression in
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tinct for liver, kidney and brain, (Supplementary ﬁle 2). Unsurprising-
ly, the variation of Igfbp5 expression in other two organs did not
correlate with ALAT and ASAT levels in serum.
The systems genetic approach was further employed to identify
the quantitative trait loci (QTLs) that speciﬁcally modulate the ex-
pression of Igfbp5 in mouse liver. No cisQTLs were determined on
Chr.1, where Igfbp5 resides (Supplementary Fig. 3A). A putative
trans-regulatory region that modulates Igfbp5 expression in liver
was identiﬁed on Chr.7. The QTL peak (135–142 Mb) comprised 83
positional candidates that may modulate hepatic Igfbp5 expression
(Supplementary Fig. 3B, Supplementary Table 1). To narrow them
down to a biologically relevant subset, genes were scrutinized by an-
alyzing their co-expression, by QTL mapping (to establish if they were
cisQTLs per se), by examining the number of SNPs, and by studying
the literature. Among the four most promising candidates (Tacc2,
Nkx1-2, Zranb1 and Ctbp) Nkx1-2 appeared the most likely one,
since it was a cisQTL, it was modulated by the same transQTL on
Chr.14 that possibly also regulates the expression of Igfbp5, and its ex-
pression positively correlated with that of Igfbp5 (Supplementary Fig.
4A–C). The almost linear relationship between Nkx1-2 expression in
the liver and the survival coefﬁcient in infectious diseases suggests
its potential important role in orchestrating inﬂammatory responses,
possibly including Igfbp5 expression (Supplementary Fig. 4D; Kotb M.,
2010, unpublished data). Although this analysis reveals Nkx1 as an in-
teresting candidate, the role of other candidate genes cannot be
excluded.
4. Discussion
The aim of this study was to investigate the role of IGFBP5 in the
liver pathogenesis in the Abcb4−/−mice, a model for chronic cholan-
giopathy. Prolonged overexpression of IGFBP5 in hepatocytes de-
creased their proliferation, reduced inﬂammation and oxidative
stress, and lowered number of activated HSC, all leading to reduced
development of liver ﬁbrosis.
IGFBP5 has cell- and tissue-type speciﬁc effects. It induces apopto-
sis in the involuting mammary gland [28] and inhibits cell prolifera-
tion in the involuting prostate gland [29], but supports the survival
of skeletal myoblast [30]. To clarify the differential role and expres-
sion of Igfbp5 in liver and other organs, its steady-state expression
was analyzed in the BXD genetic reference population. The correla-
tions with clinical features not only indicated an organ speciﬁc regu-
lation of IGFBP5, but also a role that differed between organs. This
seems to explain why IGFBP5 was found as a proﬁbrotic factor in
lung and skin [12,13], while the current study revealed its protective
effect in liver ﬁbrosis. The latter is underscored by the negative corre-
lation between Igfbp5 expression and serum parameters of liver dam-
age in IGFBP5 overexpressing Abcb4−/−mice, and in the BXD genetic
reference population. The systems genetic approach made it clear
that the relation between these liver enzyme levels and IGFBP5 goes
beyond the issue of damage in the Abcb4−/− model. In addition, a
protective effect of IGFBP5 on hepatocytes in vivo is consistent with
its prosurvival effect seen in activated HSC in vitro [11]. Reduced
liver ﬁbrosis after 12 weeks of IGFBP5 expression, as demonstrated
by considerably reduced portal bridging compared to that seen in
control animals at the time of vector administration and compared
to GFP-expressing controls (Fig. 4C and Supplementary Fig. 1A), indi-
cated involvement of IGFBP5 not only in impediment of ongoing
ﬁbrogenesis, but in reduction of the existing scar tissue.
The most likely mechanism of the anti-ﬁbrotic effect of IGFBP5 ex-
pression in the Abcb4−/− mice is a reduction of inﬂammation. The
portal inﬂammation, caused by leakage of toxic bile is one of the
most prominent pathological features in this model for chronic cho-
langiopathy [3]. Overexpression of IGFBP5 lowers the inﬂux of inﬂam-
matory cells into this area, possibly by impairing their migration [31].This would also lower the production of inﬂammatory cytokines,
known to stimulate collagen synthesis and to enhance hepatocyte
damage. The negative correlation of Igfbp5 expression with inﬂam-
mation in the BXD genetic reference population further supports
such an anti-inﬂammatory role. In addition, the systems genetics ap-
proach indicated Nkx1-2 as the putative modulator of liver Igfbp5 ex-
pression, possibly in response to an inﬂammatory assault, which
would then explain the Igfbp5 upregulation in Abcb4−/− mice upon
cholate feeding [9]. Damaged hepatocytes and activated inﬂammato-
ry cells release reactive oxygen species (ROS) and other reactive in-
termediates [32,33], which enhance the expression of proﬁbrotic
genes in human HSC and MFs [34–36]. The reduced oxidative stress
in IGFBP5 overexpressing livers is in agreement with the observed de-
crease in inﬂammation, and may additionally alleviate liver ﬁbrosis.
However, the lower inﬂux may also reduce the immune surveillance
in these livers and as such may provide protection of cancer cells.
Such a mechanism could explain the high IGFBP5 expression reported
in patients with cholangiocarcinoma [10].
IGFBP5, however, may have a more direct effect. The increased
amount of p21 in IGFBP5 overexpressing livers may be instrumental
for the reduced proliferation. p21 regulates PCNA binding to dam-
aged DNA [37], reducing its nuclear presence as seen in this study
(Fig. 2A–B). In addition, the increased presence of p21 may play a
role in senescence [38], particularly that in the ﬁbrotic regions of
IGFBP5 treated livers. Changes in gene expression proﬁles of senes-
cent HSC point to the cell cycle standstill, decreased synthesis of
ECM, and increased release of ECM remodeling enzymes [39]. In
this case, the increased expression of IGFBP5 seems aimed at reduc-
ing the pathology in this model of chronic cholangiopathy.
In conclusion, this study reveals that expression of IGFBP5 in the
Abcb4−/−mice reduces inﬂammation, oxidative stress, ECMdeposition
and hepatocyte proliferation, thereby evidently reducing liver ﬁbrosis.
Furthermore, the systems genetics approach reveals correlation be-
tween endogenous hepatic Igfbp5 expression and decrease of inﬂam-
mation in a genetic reference population, underscoring its role in
ameliorating pathology in the model for chronic cholangiopathy.
Financial support
The study was supported by a Dutch MLDS grant CG 102001.
Supplementary materials related to this article can be found on-
line at doi:10.1016/j.bbadis.2012.02.022.
Acknowledgements
We are indebted to Profs. M. Kotb and R.W. Moyer for permission
to use their unpublished phenotypic data deposited in the GeneNet-
work database. We thank Prof. Dr. R.P.J. Oude Elferink for constructive
discussions, Dr. J. Ruijter for help with quantiﬁcation in Scion Image,
and J. K. Hiralall, L. ten Bloemendaal and C. Kunne for technical
assistance.
References
[1] E. Jacquemin, J.M. de Vree, D. Cresteil, E.M. Sokal, E. Sturm, M. Dumont, G.L.
Scheffer, M. Paul, M. Burdelski, P.J. Bosma, O. Bernard, M. Hadchouel, R.P.
Elferink, The wide spectrum of multidrug resistance 3 deﬁciency: from neonatal
cholestasis to cirrhosis of adulthood, Gastroenterology 120 (2001) 1448–1458.
[2] M. Katzenellenbogen, O. Pappo, H. Barash, N. Klopstock, L. Mizrahi, D. Olam, J.
Jacob-Hirsch, N. Amariglio, G. Rechavi, L.A. Mitchell, R. Kohen, E. Domany, E.
Galun, D. Goldenberg, Multiple adaptive mechanisms to chronic liver disease
revealed at early stages of liver carcinogenesis in the Mdr2-knockout mice, Can-
cer Res. 66 (2006) 4001–4010.
[3] T.H. Mauad, C.M. van Nieuwkerk, K.P. Dingemans, J.J. Smit, A.H. Schinkel, R.G.
Notenboom, M.A. van den Bergh Weerman, R.P. Verkruisen, A.K. Groen, R.P.
Oude Elferink, Mice with homozygous disruption of the mdr2 P-glycoprotein
gene. A novel animal model for studies of nonsuppurative inﬂammatory cholan-
gitis and hepatocarcinogenesis, Am. J. Pathol. 145 (1994) 1237–1245.
1003A. Sokolović et al. / Biochimica et Biophysica Acta 1822 (2012) 996–1003[4] R.C. Benyon, M.J. Arthur, Extracellular matrix degradation and the role of hepatic
stellate cells, Semin. Liver Dis. 21 (2001) 373–384.
[5] D. Gatti, A. Maki, E.J. Chesler, R. Kirova, O. Kosyk, L. Lu, K.F. Manly, R.W. Williams,
A. Perkins, M.A. Langston, D.W. Threadgill, I. Rusyn, Genome-level analysis of ge-
netic regulation of liver gene expression networks, Hepatology 46 (2007)
548–557.
[6] D. Schuppan, M. Ruehl, R. Somasundaram, E.G. Hahn, Matrix as a modulator of he-
patic ﬁbrogenesis, Semin. Liver Dis. 21 (2001) 351–372.
[7] S.L. Friedman, Mechanisms of disease: mechanisms of hepatic ﬁbrosis and thera-
peutic implications, Nat. Clin. Pract. Gastroenterol. Hepatol. 1 (2004) 98–105.
[8] M. Pinzani, K. Rombouts, Liver ﬁbrosis: from the bench to clinical targets, Dig.
Liver Dis. 36 (2004) 231–242.
[9] W. Boers, S. Aarrass, C. Linthorst, M. Pinzani, R.O. Elferink, P. Bosma, Transcrip-
tional proﬁling reveals novel markers of liver ﬁbrogenesis: gremlin and insulin-
like growth factor-binding proteins, J. Biol. Chem. 281 (2006) 16289–16295.
[10] R. Nishino, M. Honda, T. Yamashita, H. Takatori, H. Minato, Y. Zen, M. Sasaki, H.
Takamura, K. Horimoto, T. Ohta, Y. Nakanuma, S. Kaneko, Identiﬁcation of novel
candidate tumour marker genes for intrahepatic cholangiocarcinoma, J. Hepatol.
49 (2008) 207–216.
[11] A. Sokolovic, M. Sokolovic, W. Boers, R.P. Elferink, P.J. Bosma, Insulin-like growth
factor binding protein 5 enhances survival of LX2 human hepatic stellate cells,
Fibrogenesis Tissue Repair 3 (2010) 3.
[12] J.M. Pilewski, L. Liu, A.C. Henry, A.V. Knauer, C.A. Feghali-Bostwick, Insulin-like
growth factor binding proteins 3 and 5 are overexpressed in idiopathic pulmo-
nary ﬁbrosis and contribute to extracellular matrix deposition, Am. J. Pathol.
166 (2005) 399–407.
[13] H. Yasuoka, D.M. Jukic, Z. Zhou, A.M. Choi, C.A. Feghali-Bostwick, Insulin-like
growth factor binding protein 5 induces skin ﬁbrosis: a novel murine model for
dermal ﬁbrosis, Arthritis Rheum. 54 (2006) 3001–3010.
[14] D.R. Clemmons, Insulin-like growth factor binding proteins and their role in con-
trolling IGF actions, Cytokine Growth Factor Rev. 8 (1997) 45–62.
[15] A.C. Nathwani, J.T. Gray, C.Y. Ng, J. Zhou, Y. Spence, S.N. Waddington, E.G.
Tuddenham, G. Kemball-Cook, J. McIntosh, M. Boon-Spijker, K. Mertens, A.M.
Davidoff, Self-complementary adeno-associated virus vectors containing a novel
liver-speciﬁc human factor IX expression cassette enable highly efﬁcient trans-
duction of murine and nonhuman primate liver, Blood 107 (2006) 2653–2661.
[16] J. Seppen, C. Bakker, B. de Jong, C. Kunne, K. van den Oever, K. Vandenberghe, R.
de Waart, J. Twisk, P. Bosma, Adeno-associated virus vector serotypes mediate
sustained correction of bilirubin UDP glucuronosyltransferase deﬁciency in rats,
Mol. Ther. 13 (2006) 1085–1092.
[17] R. vanWestrhenen, D.R. deWaart, S. Akman, R.T. Krediet, Assessment of peritone-
al ﬁbrosis by conventional light microscopy and hydroxyproline measurements,
Perit. Dial. Int. 24 (2004) 290–292.
[18] F. Tietze, Enzymic method for quantitative determination of nanogram amounts
of total and oxidized glutathione: applications to mammalian blood and other tis-
sues, Anal. Biochem. 27 (1969) 502–522.
[19] M. Sokolovic, D. Wehkamp, A. Sokolovic, J. Vermeulen, L.A. Gilhuijs-Pederson, R.I.
van Haaften, Y. Nikolsky, C.T. Evelo, A.H. van Kampen, T.B. Hakvoort, W.H. Lamers,
Fasting induces a biphasic adaptive metabolic response in murine small intestine,
BMC Genomics 8 (2007) 361.
[20] E.E. Geisert, L. Lu, N.E. Freeman-Anderson, J.P. Templeton, M. Nassr, X. Wang, W.
Gu, Y. Jiao, R.W. Williams, Gene expression in the mouse eye: an online resource
for genetics using 103 strains of mice, Mol. Vis. 15 (2009) 1730–1763.
[21] D. Grimm, K. Pandey, H. Nakai, T.A. Storm, M.A. Kay, Liver transduction with re-
combinant adeno-associated virus is primarily restricted by capsid serotype not
vector genotype, J. Virol. 80 (2006) 426–439.
[22] C.M. van Nieuwkerk, R.P. Elferink, A.K. Groen, R. Ottenhoff, G.N. Tytgat, K.P.
Dingemans, M.A. van den BerghWeerman, G.J. Offerhaus, Effects of ursodeoxycholateand cholate feeding on liver disease in FVBmicewith a disruptedmdr2P-glycoprotein
gene, Gastroenterology 111 (1996) 165–171.
[23] S.D. Kershenobich, A.B. Weissbrod, Liver ﬁbrosis and inﬂammation. A review,
Ann. Hepatol. 2 (2003) 159–163.
[24] C.S. Lieber, Alcoholic fatty liver: its pathogenesis and mechanism of progression
to inﬂammation and ﬁbrosis, Alcohol 34 (2004) 9–19.
[25] C.A. Argmann, P. Chambon, J. Auwerx, Mouse phenogenomics: the fast track to
“systems metabolism”, Cell Metab. 2 (2005) 349–360.
[26] E.J. Chesler, L. Lu, S. Shou, Y. Qu, J. Gu, J. Wang, H.C. Hsu, J.D. Mountz, N.E. Baldwin,
M.A. Langston, D.W. Threadgill, K.F. Manly, R.W. Williams, Complex trait analysis
of gene expression uncovers polygenic and pleiotropic networks that modulate
nervous system function, Nat. Genet. 37 (2005) 233–242.
[27] H. Koutnikova, M. Laakso, L. Lu, R. Combe, J. Paananen, T. Kuulasmaa, J. Kuusisto,
H.U. Haring, T. Hansen, O. Pedersen, U. Smith, M. Hanefeld, R.W. Williams, J.
Auwerx, Identiﬁcation of the UBP1 locus as a critical blood pressure determinant
using a combination of mouse and human genetics, PLoS Genet. 5 (2009)
e1000591.
[28] E. Tonner, M.C. Barber, M.T. Travers, A. Logan, D.J. Flint, Hormonal control of
insulin-like growth factor-binding protein-5 production in the involuting mam-
mary gland of the rat, Endocrinology 138 (1997) 5101–5107.
[29] L.N. Thomas, P. Cohen, R.C. Douglas, C. Lazier, R.S. Rittmaster, Insulin-like growth
factor binding protein 5 is associated with involution of the ventral prostate in
castrated and ﬁnasteride-treated rats, Prostate 35 (1998) 273–278.
[30] K.A. Meadows, J.M. Holly, C.E. Stewart, Tumor necrosis factor-alpha-induced apo-
ptosis is associated with suppression of insulin-like growth factor binding
protein-5 secretion in differentiating murine skeletal myoblasts, J. Cell. Physiol.
183 (2000) 330–337.
[31] E. Novo, C. Busletta, L.V. di Bonzo, D. Povero, C. Paternostro, K. Mareschi, I. Ferrero,
E. David, C. Bertolani, A. Caligiuri, S. Cannito, E. Tamagno, A. Compagnone, S.
Colombatto, F. Marra, F. Fagioli, M. Pinzani, M. Parola, Intracellular reactive oxy-
gen species are required for directional migration of resident and bone
marrow-derived hepatic pro-ﬁbrogenic cells, J. Hepatol. 54 (5) (2011) 964–974.
[32] P. Greenwel, J.A. Dominguez-Rosales, G. Mavi, A.M. Rivas-Estilla, M. Rojkind, Hy-
drogen peroxide: a link between acetaldehyde-elicited alpha1(I) collagen gene
up-regulation and oxidative stress in mouse hepatic stellate cells, Hepatology
31 (2000) 109–116.
[33] N. Nieto, Oxidative-stress and IL-6 mediate the ﬁbrogenic effects of [corrected]
Kupffer cells on stellate cells, Hepatology 44 (2006) 1487–1501.
[34] R. Bataller, P. Sancho-Bru, P. Gines, D.A. Brenner, Liver ﬁbrogenesis: a new role for
the renin-angiotensin system, Antioxid. Redox Signal. 7 (2005) 1346–1355.
[35] E. Novo, F. Marra, E. Zamara, B.L. Valfre di, A. Caligiuri, S. Cannito, C. Antonaci, S.
Colombatto, M. Pinzani, M. Parola, Dose dependent and divergent effects of su-
peroxide anion on cell death, proliferation, and migration of activated human he-
patic stellate cells, Gut 55 (2006) 90–97.
[36] E. Zamara, E. Novo, F. Marra, A. Gentilini, R.G. Romanelli, A. Caligiuri, G. Robino, E.
Tamagno, M. Aragno, O. Danni, R. Autelli, S. Colombatto, M.U. Dianzani, M.
Pinzani, M. Parola, 4-Hydroxynonenal as a selective pro-ﬁbrogenic stimulus for
activated human hepatic stellate cells, J. Hepatol. 40 (2004) 60–68.
[37] O. Cazzalini, P. Perucca, M. Savio, D. Necchi, L. Bianchi, L.A. Stivala, B. Ducommun,
A.I. Scovassi, E. Prosperi, Interaction of p21(CDKN1A) with PCNA regulates the
histone acetyltransferase activity of p300 in nucleotide excision repair, Nucleic
Acids Res. 36 (2008) 1713–1722.
[38] B. Zhao, E.K. Benson, R. Qiao, X. Wang, S. Kim, J.J. Manfredi, S.W. Lee, S.A.
Aaronson, Cellular senescence and organismal ageing in the absence of
p21(CIP1/WAF1) in ku80(−/−) mice, EMBO Rep. 10 (2009) 71–78.
[39] V. Krizhanovsky, M. Yon, R.A. Dickins, S. Hearn, J. Simon, C. Miething, H. Yee, L.
Zender, S.W. Lowe, Senescence of activated stellate cells limits liver ﬁbrosis, Cell
134 (2008) 657–667.
